Search results for PX-TA1006

Bevacizumab Biosimilar – Anti-VEGF mAb – Research Grade, ProteoGenix, PX-TA1006

Description of Bevacizumab Biosimilar - Anti-VEGF mAb - Research Grade General information about Bevacizumab Bevacizumab, is classified as a monoclonal antibody and/or anti-angiogenesis drug. It is a comparatively new type of cancer therapy. Antibodies are an essential part of the immune system. The body creates antibodies in response to an antigen entering the body. These antibodies attach themselves to the antigen, to mark it for destruction by the body’s immune system. Bevacizumab allows human body to target specific cells, causing less toxicity to healthy cells. It works by interfering with the process of angiogenesis by targeting and inhibiting human vascular endothelial growth factor (VEGF). VEGF is a cytokine (a small protein released by cells that have specific effects on the behavior of cells) which when it interacts with its receptors in the cell leads to new blood vessel formation or angiogenesis. This product is for research use only.